Week In Review: Xinbang Pharma Acquires Chinese Peptide Co. For $323 Million

Concord Medical (NYSE: CCM), which operates radiotherapy and diagnostic imaging centers in China hospitals, will collaborate with the MD Anderson Cancer Center at the University of Texas to develop state-of-the-art cancer care programs (see story). Concord has begun operating oncology-focused hospitals, and it will implement the cancer program in its hospitals in Beijing, Shanghai and Guangzhou. The agreement is a first for MD Anderson in Asia. It will cover most provinces in China and in Singapore, and it will be an exclusive relationship for the Beijing and Shanghai hospitals. 

Trials and Approvals

Bayer AG (XETRA: BAYN) announced that the CFDA has approved Xarelto (rivaroxaban), a once-daily oral anticoagulant, for two new anti-clotting indications: strokes and deep vein thrombosis (see story). Xarelto has been on the China market since 2009 to prevent clots following hip or knee replacement surgeries. Both of the new indications were approved based on data submitted from Bayer's large-enrollment global trials. 

Shanghai Generon Corporation has been granted FDA approval to begin a US Phase IIa clinical trial of its novel recombinant human interleukin (see story). The molecule will be tested as a treatment for graft-versus-host disease in the lower intestines of patients undergoing hematopoietic stem cell transplants, a side-effect with incidence as high as 50%. Generon says the drug offers a treatment alternative that, instead of increasing immune suppression, aims to regenerate the intestines. 

PharmaEngine (TWO:4162) of Taiwan announced that its licensing partner, Merrimack Pharma (NSDQ:MACK) of Boston, and its sublicensing partner, Baxter International (NYSE: BAX), have applied for European marketing approval of MM-398, a liposome-encased form of irinotecan (see story). The drug is indicated to treat metastatic pancreatic cancer in patients previously treated with gemcitabine. PharmaEngine retains rights to the drug in Taiwan, but out-licensed the global rights (ex-Taiwan) to Merrimack in 2011 for $10 million upfront and $210 million in milestones, plus royalties. 

View single page >> |

Disclosure: None

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.


Leave a comment to automatically be entered into our contest to win a free Echo Show.